EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study)

Petra Staubach, Elisabeth Wurzer, Hans Joachim Hutt, Ralph von Kiedrowski

Dermatology · 2023

DOI: 10.1159/000527496 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Dermatology, 2023. Verfasst von Petra Staubach und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Medical Center, Mainz, Germany. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim: Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol/betamethasone (Cal/BD) aerosol foam for the treatment of patients with scalp psoriasis. However, data on the real-world effectiveness of Cal/BD aerosol foam in this subgroup of patients are lacking. Therefore, this study investigated the effectiveness and tolerability of 4 weeks’ treatment with Cal/BD aerosol foam in patients with scalp psoriasis in everyday clinical practice. Methods: This prospective, non-interventional multicenter study involved 217 adults with scalp psoriasis who were treated with Cal/BD aerosol foam for 4 weeks. Primary endpoints included the proportion of patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsPsoriasisAdultHumansQuality of LifeProspective StudiesScalpBetamethasoneDrug CombinationsPruritusAerosolsTreatment OutcomeCalcitriol

Stichwörter der Autor:innen

Aerosol foamBetamethasoneCalcipotriolScalp psoriasis

Substanzen

Dermatologic AgentsBetamethasoneDrug CombinationsAerosolsbetamethasone dipropionate, calcipotriol drug combinationCalcitriolcalcipotriene

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, University Medical Center, Mainz, Germany.
  • LEO Pharma GmbH, Neu-Isenburg, Germany.
  • Dermatologische Spezialpraxis für chronisch-entzündliche System-Dermatosen, Dermato-Onkologie und Allergologie, Selters (Westerwald), Germany.

Zitieren

APA

Staubach, P., Wurzer, E., Hutt, H. J., & von Kiedrowski, R. (2023). Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). Dermatology. https://doi.org/10.1159/000527496

Vancouver

Staubach P, Wurzer E, Hutt HJ, von Kiedrowski R. Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). Dermatology. 2023. doi:10.1159/000527496

BibTeX
@article{Staubach2023,
  author = {Staubach, Petra and Wurzer, Elisabeth and Hutt, Hans Joachim and von Kiedrowski, Ralph},
  title = {Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study)},
  journal = {Dermatology},
  year = {2023},
  doi = {10.1159/000527496}
}
Kostenlos starten →